McDonald’s Corp. has finally updated its antibiotics policy that calls for reduced antibiotic usage after a two-year delay.
The fast-food giant’s new policy revealed in Decemebr follows guidelines set out by the World Health Organization (WHO), the World Organization for Animal Health, and other public and animal health groups.
According to McDonald’s, they will focus on the responsible use of medically important antibiotics and be aligned with WHO Guidelines on Antimicrobial Resistance.
The company added that its policy does not permit the routine use of medically important antibiotics for growth promotion or tdisease prevention.
It is committed to usage reduction, where possible without adverse effects on animal health and welfare.
The company has established market-specific targets for the responsible use of antibiotics for 10 in-scope markets, representing over 80 percent of its global beef supply chain.
In 2023, McDonald’s plans to share an update on its antibiotic usage.
However, the Natural Resources Defense Council (NRDC) criticized McDonald’s for failing to detail a rollout plan or a completion date to ensure accountability across the supply chain.
According to Lena Brook, director of food campaigns at NRDC, it is especially disappointing given that McDonald’s, the world’s largest beef buyer, chose optics over substance with its new beef policy update despite the urgency of the global antibiotic resistance crisis.
McDonald’s earned a grade of C from the NDRC for its previous policy. NDRC called McDonald’s updated policy a “new, weaker approach.”


Kioxia Rules Out SK Hynix Manufacturing Partnership
Qualcomm Stock Jumps on Amazon AI Chip Deal
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak
UK Food Inflation Forecast to Hit 6.4% by Mid-2027
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
US Bans Canadian Alcohol, Motorcycles as Trade War Escalates
Fitch Eyes Japan Budget for Fiscal Discipline
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak
TSMC August Revenue Jumps 53% on AI Chip Demand
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
Huawei, Chinese AI Chipmakers Raise Prices as HBM Shortage Bites
Treasury Buyback Fails to Cool Long-Term Yields
OpenAI Weighs AI Development Slowdown Over Safety Risks
German Inflation Accelerates to 2.9% in August
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 



